Apremilast

Research use only, not for human use.

Apremilast (CC-10004) is a potent, orally active PDE4 inhibitor with IC50 of 74 nM, inhibits TNF-α production in LPS-stimulated hPBMCs with IC50 of 77 nM.

Apremilast (CC-10004) is a potent, orally active PDE4 inhibitor with IC50 of 74 nM, inhibits TNF-α production in LPS-stimulated hPBMCs with IC50 of 77 nM; inhibits PBMC production of the chemokines CXCL9 and CXCL10, IFN-gamma and TNF-alpha, and IL-2, IL-12 and IL-23, also inhibits TNF-α by NK cells and keratinocytes; significantly reduces epidermal thickness and proliferation, decreases the general histopathological appearance of psoriasiform features and reduces expression of TNF-α, human leukocyte antigen-DR and intercellular adhesion molecule-1 in the lesioned skin in model of psoriasis.Psoriasis Approved

CC 10004;CC10004;CC-10004

Angiogenesis

PDE

PDE4

Inflammation/Immunology

Psoriasis

608141-41-9

460.50

C22H24N2O7S

>98% (HPLC)

10 mM in DMSO

CC(NC1=CC=CC(C(N2[C@@H](C3=CC=C(OC)C(OCC)=C3)CS(=O)(C)=O)=O)=C1C2=O)=O

Acetamide, N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]-

(-20℃)

With Ice Pack

≥ 2 years